Aflibercept as First-Line Therapy in Patients with Treatment-Naive Neovascular Age-Related Macular Degeneration: Prospective Case Series Analysis in Real-Life Clinical Practice

Autores de IIS La Fe

• Patricia Udaondo Mirete

  Autor

• David Salom Alonso

  Autor

• Salvador García Delpech

  Autor

• Angel Luis Cisneros Lanuza

  Autor

Grupos

• 

  Biomedicina Molecular, Celular y Genómica

Abstract

Purpose: To assess the 13-month effectiveness and safety of aflibercept in naive patients with neovascular age-related macular degeneration (nvAMD) in a real-life clinical setting. Methods: Thirty-two treatment-naive patients with nvAMD participated in a prospective two-center study. Patients received intravitreal injections of aflibercept (Eylea (R)), a loading dose of three monthly injections (2 mg/0.05 ml) every 4 weeks for the first 3 months, followed by intravitreal injections every 2 months. Results: At 3 and 13 months, the mean best-corrected visual acuity improved significantly as compared with baseline (logMAR 0.53 +/- 0.30 and 0.55 +/- 0.32 vs. 0.30 +/- 0.24, respectively, p < 0.001). At 3 and 13 months, 46.8% of patients (15/32) gained >= 15 ETDRS letters. The mean decrease in central macular thickness was also significant at 3 months (252 +/- 35 mu m) and at 13 months (249 +/- 38 mu m) as compared with pretreatment values (383 +/- 76 mu m) (p < 0.01). Also, 50% resolution of pigment epithelial detachment (PED) was observed in 8 out of 9 eyes (88.9%) with PED at baseline. Intravitreal injections were well tolerated and no adverse events were recorded. Conclusion: Aflibercept was effective and safe for treating nvAMD in naive patients in routine daily practice. (C) 2016 S. Karger AG, Basel

Keywords

• Aflibercept; Eylea (R); Macular degeneration; Prospective studies; Receptors; Vascular endothelial growth factor